These Analysts Revise Their Forecasts On ResMed Following Q1 Results - ResMed (NYSE:RMD)

Core Insights - ResMed Inc. reported better-than-expected earnings for Q1, with earnings of $2.55 per share, surpassing the analyst consensus estimate of $2.50 per share [1] - The company achieved quarterly sales of $1.336 billion, exceeding the analyst consensus estimate of $1.331 billion [1] Financial Performance - The company experienced a 9% year-over-year revenue growth, alongside a 280 basis points expansion in non-GAAP gross margin [2] - Non-GAAP EPS growth was reported at 16%, indicating strong bottom-line performance [2] Market Reaction - Following the earnings announcement, ResMed shares fell by 0.5%, closing at $252.26 [2] Analyst Ratings and Price Targets - Mizuho analyst maintained an Outperform rating but lowered the price target from $310 to $300 [5] - Keybanc analyst maintained an Overweight rating and raised the price target from $298 to $299 [5]